These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 11336917

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.
    Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM.
    J Bone Miner Res; 2000 Apr; 15(4):640-9. PubMed ID: 10780856
    [Abstract] [Full Text] [Related]

  • 4. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
    Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou N.
    Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
    [Abstract] [Full Text] [Related]

  • 5. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [Abstract] [Full Text] [Related]

  • 6. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
    Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D.
    Am J Pathol; 2003 Nov; 163(5):2021-31. PubMed ID: 14578201
    [Abstract] [Full Text] [Related]

  • 7. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
    Wittrant Y, Théoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Rédini F.
    Biochim Biophys Acta; 2004 Sep 20; 1704(2):49-57. PubMed ID: 15363860
    [Abstract] [Full Text] [Related]

  • 8. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P, Persson E, Conaway HH, Lerner UH.
    J Immunol; 2002 Sep 15; 169(6):3353-62. PubMed ID: 12218157
    [Abstract] [Full Text] [Related]

  • 9. Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor.
    Hu Y, Yu S.
    Zhonghua Bing Li Xue Za Zhi; 2002 Apr 15; 31(2):128-31. PubMed ID: 12419159
    [Abstract] [Full Text] [Related]

  • 10. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T.
    Endocrinology; 2000 Sep 15; 141(9):3478-84. PubMed ID: 10965921
    [Abstract] [Full Text] [Related]

  • 11. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone.
    Si AI, Huang L, Xu J, Kumta SM, Wood D, Zheng MH.
    J Cell Biochem; 2003 Aug 15; 89(6):1154-63. PubMed ID: 12898514
    [Abstract] [Full Text] [Related]

  • 12. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT.
    J Bone Miner Res; 2001 Oct 15; 16(10):1787-94. PubMed ID: 11585342
    [Abstract] [Full Text] [Related]

  • 13. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
    Roux S, Mariette X.
    Leuk Lymphoma; 2004 Jun 15; 45(6):1111-8. PubMed ID: 15359989
    [Abstract] [Full Text] [Related]

  • 14. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K.
    Cancer Res; 2001 Feb 15; 61(4):1637-44. PubMed ID: 11245477
    [Abstract] [Full Text] [Related]

  • 15. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
    Hofbauer LC, Neubauer A, Heufelder AE.
    Cancer; 2001 Aug 01; 92(3):460-70. PubMed ID: 11505389
    [Abstract] [Full Text] [Related]

  • 16. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.
    Karst M, Gorny G, Galvin RJ, Oursler MJ.
    J Cell Physiol; 2004 Jul 01; 200(1):99-106. PubMed ID: 15137062
    [Abstract] [Full Text] [Related]

  • 17. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
    Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM.
    Rheumatology (Oxford); 2001 Jun 01; 40(6):623-30. PubMed ID: 11426018
    [Abstract] [Full Text] [Related]

  • 18. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M, Takahashi N, Udagawa N, Miyaura C, Suda K, Woo JT, Martin TJ, Nagai K, Suda T.
    Endocrinology; 2000 Dec 01; 141(12):4711-9. PubMed ID: 11108286
    [Abstract] [Full Text] [Related]

  • 19. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
    Sun SG, Lau YS, Itonaga I, Sabokbar A, Athanasou NA.
    J Pathol; 2006 May 01; 209(1):114-20. PubMed ID: 16482498
    [Abstract] [Full Text] [Related]

  • 20. Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening.
    Gehrke T, Sers C, Morawietz L, Fernahl G, Neidel J, Frommelt L, Krenn V.
    Scand J Rheumatol; 2003 May 01; 32(5):287-94. PubMed ID: 14690142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.